Literature DB >> 25081755

The neuroblastoma and ganglion components of nodular ganglioneuroblastoma are genetically similar: evidence against separate clonal origins.

Paola Angelini1, Sylvain Baruchel2, Paula Marrano3, Meredith S Irwin2, Paul S Thorner4.   

Abstract

Nodular ganglioneuroblastoma is characterized by a macroscopic nodule of neuroblastoma within a ganglioneuromatous component. These two components have been considered to originate from separate clones, with the neuroblastoma clone accounting for the clinical behavior of nodular ganglioneuroblastoma. In order to investigate the clonal origin of the cellular components (neuroblasts, ganglion cells, and Schwann cells) of nodular ganglioneuroblastoma, paraffin-embedded tumor samples from eight cases were analyzed by single nucleotide polymorphism array and in situ hybridization. DNA was extracted separately from neuroblastomatous and ganglioneuromatous areas. By in situ hybridization, MYCN gain (4-10 gene copies/nucleus) was detected in 7/8 neuroblastoma samples. In ganglioneuromatous regions, gains were also detected in ganglion cells but not in Schwann cells. Single-nucleotide polymorphism array studies identified chromosome losses (11q and 14q) and gains (12, 13q, 17q and 18q) in the neuroblastoma component, whereas the ganglioneuromatous component showed fewer or no genetic alterations. There were no unique copy number changes distinguishing nodular ganglioneuroblastoma from other subtypes of neuroblastoma. By in situ hybridization, ganglion cells but not Schwann cells showed the same alterations detected in neuroblasts. Thus, neuroblasts and ganglion cells in nodular ganglioneuroblastoma are genetically related and may arise from the same clone. In contrast, the Schwann cells have a different origin and may be derived from a non-neoplastic neural crest precursor. Our results suggest that the clinical behavior of nodular ganglioneuroblastoma cannot be explained by the presence of separate clones with distinct genetic signatures.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25081755     DOI: 10.1038/modpathol.2014.90

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  44 in total

1.  Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell.

Authors:  J Mora; N K Cheung; G Juan; P Illei; I Cheung; M Akram; S Chi; M Ladanyi; C Cordon-Cardo; W L Gerald
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

2.  Laser-capture microdissected schwannian and neuroblastic cells in stage 4 neuroblastomas have the same genetic alterations.

Authors:  J Mora; M Akram; N K Cheung; L Chen; W L Gerald
Journal:  Med Pediatr Oncol       Date:  2000-12

3.  International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

Authors:  H Shimada; S Umehara; Y Monobe; Y Hachitanda; A Nakagawa; S Goto; R B Gerbing; D O Stram; J N Lukens; K K Matthay
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

Review 4.  Recent advances in neuroblastoma.

Authors:  John M Maris
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

5.  Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular.

Authors:  S Umehara; A Nakagawa; K K Matthay; J N Lukens; R C Seeger; D O Stram; R B Gerbing; H Shimada
Journal:  Cancer       Date:  2000-09-01       Impact factor: 6.860

6.  Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study.

Authors:  H M Katzenstein; L C Bowman; G M Brodeur; P S Thorner; V V Joshi; E I Smith; A T Look; S T Rowe; M B Nash; T Holbrook; C Alvarado; P V Rao; R P Castleberry; S L Cohn
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

7.  Evidence for molecular heterogeneity in human ganglioneuroblastoma.

Authors:  M L Schmidt; H R Salwen; D Chagnovich; K D Bauer; S E Crawford; S L Cohn
Journal:  Pediatr Pathol       Date:  1993 Nov-Dec

8.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

9.  Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization.

Authors:  Paola Scaruffi; Simona Coco; Francisco Cifuentes; Domenico Albino; Manoj Nair; Raffaella Defferrari; Katia Mazzocco; Gian Paolo Tonini
Journal:  Cancer Genet Cytogenet       Date:  2007-08

10.  Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.

Authors:  G Schleiermacher; J Michon; I Huon; C Dubois d'Enghien; J Klijanienko; H Brisse; A Ribeiro; V Mosseri; H Rubie; C Munzer; C Thomas; D Valteau-Couanet; A Auvrignon; D Plantaz; O Delattre; J Couturier
Journal:  Br J Cancer       Date:  2007-06-19       Impact factor: 7.640

View more
  1 in total

Review 1.  11q deletion in neuroblastoma: a review of biological and clinical implications.

Authors:  Vid Mlakar; Simona Jurkovic Mlakar; Gonzalo Lopez; John M Maris; Marc Ansari; Fabienne Gumy-Pause
Journal:  Mol Cancer       Date:  2017-06-29       Impact factor: 27.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.